Hong Kong After the Hong Kong Exchanges and Clearing Limited’s (HKEX) 2018 move to allow pre-revenue biotech companies to raise capital in Hong Kong under its Chapter 18A mechanism, biotech listings surged with pre-clinical companies chosing to list on HKEX as a means of accessing global capital, raising around HKD 118 billion…
Taiwan In just 35 years, Taiwan has gone from having no biotechs on the TAIEX and Taiwan OTC stock exchanges to 124 listed firms with a combined market capitalization of more than USD 30 billion by 2020, as the below chart from the Carnegie Endowment for International Peace shows. In 2019,…
China 2020 has been eventful – perhaps the understatement of the year – but despite the novel coronavirus being discovered in China around the beginning of 2020, the country bounced back from the COVID-19 outbreaks by mid-year to deliver the hottest year for Chinese biopharma yet. The Chinese biopharma sector…
South Korea South Korea is the 12th largest healthcare market globally with a market size of around USD 20 billion in 2019. With the government’s plans to invest over USD 1.7 billion in its biopharma and biotech sectors over the next five years, the country’s prominence in the global biopharma landscape will…
liposome A 2006 article in CommonWealth Magazine detailing the genesis of this company reported that TLC had managed to “break out from the typical dilemma of ordinary biotech firms—to either engage in low cost, high competition generic drug manufacturing or expensive, time-consuming new drug development—by opening up a third road of…
See our Cookie Privacy Policy Here